Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $42.3 million.

  • Beam Therapeutics' Accumulated Expenses fell 1826.38% to $42.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.3 million, marking a year-over-year decrease of 1826.38%. This contributed to the annual value of $47.5 million for FY2024, which is 5749.03% down from last year.
  • Latest data reveals that Beam Therapeutics reported Accumulated Expenses of $42.3 million as of Q3 2025, which was down 1826.38% from $40.9 million recorded in Q2 2025.
  • In the past 5 years, Beam Therapeutics' Accumulated Expenses registered a high of $111.7 million during Q4 2023, and its lowest value of $15.0 million during Q1 2021.
  • Over the past 5 years, Beam Therapeutics' median Accumulated Expenses value was $38.6 million (recorded in 2022), while the average stood at $43.6 million.
  • As far as peak fluctuations go, Beam Therapeutics' Accumulated Expenses surged by 17188.28% in 2021, and later plummeted by 6502.31% in 2025.
  • Beam Therapeutics' Accumulated Expenses (Quarter) stood at $28.9 million in 2021, then skyrocketed by 72.58% to $49.9 million in 2022, then surged by 123.72% to $111.7 million in 2023, then plummeted by 57.49% to $47.5 million in 2024, then fell by 10.86% to $42.3 million in 2025.
  • Its Accumulated Expenses was $42.3 million in Q3 2025, compared to $40.9 million in Q2 2025 and $30.2 million in Q1 2025.